drugset / Trial / NCT06107894
TIL Therapy for Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer. NEOG-100, an autologous tumor infiltrating lymphocytes (TILs), is infused intravenously into the patient after non-myeloablative (NMA) lymphodepletion treatment.
Timeline
- Start
- 2024-01
- Primary completion
- 2025-09
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 2 iu | Subcutaneous |